Hong Kong – September 07, 2026 -- Akeso, Inc. (9926.HK) said its bispecific antibody ivonescimab produced a statistically significant and clinically meaningful overall survival benefit versus Merck's pembrolizumab in a pre-specified interim analysis of the Phase III HARMONi-2 trial, as assessed by an Independent Data Monitoring Committee.

Baltimore – September 07, 2026 -- Nanochon, Inc. has completed the first procedure in its First-in-Human clinical study for ChondrograftTM, a 3D-printed implant targeting articular cartilage defects of the knee, with the surgery performed at The Panama Clinic in Panama City.

Thousand Oaks, Calif. – September 07, 2026 -- Amgen (NASDAQ: AMGN) will present at the 2026 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, September 10, 2026.

Amgen's CFO and top medical and marketing executives will address investors

Thomas Dittrich, executive vice president and chief financial officer, Paul Burton, M.D., Ph.D., senior vice president and chief medical officer, and Kave Niksefat, senior vice president of Global Marketing and Access, will represent Amgen at the conference.

Berlin – September 07, 2026 -- Germany's largest pharmaceutical trade association, Pharma Deutschland, has warned that new cost-containment measures under the GKV-BStabG threaten drug supply, innovation, and investment in the country, even as it welcomes a fresh round of government dialogue on AMNOG reform.

Daejeon – – September 07, 2026 -- Alteogen Inc. (KOSDAQ: 196170) has signed an option and license agreement with Novartis worth up to US$3,223 million, granting the Swiss drugmaker rights to develop subcutaneous formulations for multiple Novartis products using Alteogen's ALT-B4 hyaluronidase.

Hod Hasharon, Israel & Shanghai – September 07, 2026 -- Raziel Therapeutics and Fosun Pharma reported that RZL-012, an injectable lipolytic drug for submental fat reduction, met every primary and secondary endpoint in a 480-patient Phase 3 trial in China, with the primary responder rate outperforming placebo by 30 percentage points after a single treatment cycle.

Schlieren – September 07, 2026 -- NovaGo Therapeutics AG has closed a Series B financing round of CHF 24 million ($30 million), led by Neurimmune and Pureos, to fund a proof-of-concept trial for its anti-Nogo-A antibody in acute spinal cord injury.

The equity round drew participation from existing and new investors and was supplemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life.

Singapore – September 07, 2026 -- Haier Biomedical (SHA: 688139) reported that revenue from pharmaceutical clients rose 23% year-on-year in the first half of 2026, while laboratory solutions revenue grew 19%, as the company unveiled new automated bio-storage and connected pharmaceutical technologies at the ISPE Singapore Conference & Exhibition 2026.

Menlo Park – September 7, 2026 -- GRAIL, Inc. (Nasdaq: GRAL) will present at Morgan Stanley's 24th Annual Global Healthcare Conference in New York on Monday, September 14, at 11:30 a.m. ET.

GRAIL management to address investors at flagship healthcare investment event

The company's leadership team will speak directly to institutional investors and analysts at the closely watched conference, which draws major players across the healthcare and life sciences sector.

Pleasanton – September 07, 2026 -- Veeva Systems (NYSE: VEEV) has launched Veeva Falcon Safety, an AI agent product designed to streamline adverse event intake, case processing and follow-up for biopharmaceutical companies of all sizes, cutting costs while maintaining regulatory compliance.